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Antiviral therapy of chronic hepatitis B: Opportunities
and challenges in Asiaq
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Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 199 Tung Hwa North Road, Taipei, TaiwanAsia comprises more than 40 countries encompassing a wide geographic area with a very large population. Many of
these countries have low-income economies together with high endemicity of chronic hepatitis B virus (HBV) infection,
which is usually acquired perinatally or during early childhood. The well elucidated natural history of chronic HBV infec-
tion, together with the extensive research and the longest experience in the use of therapeutic agents in Asia have provided
a great opportunity for Asian patients to beneﬁt from recent advancements. However, treatment of chronic HBV infection
is a complex task that requires individualized assessment, thus representing a great challenge for general physicians. The
inherent problems of the drugs currently available, together with a lack of awareness of the disease among patients, gov-
ernment, and healthcare practitioners are obstacles to proper management of HBV. The most critical challenge and obsta-
cle is the high cost of medical care and antiviral drugs. Lack of adequate reimbursement for treatment and diagnostic
testing makes adherence to treatment guidelines impossible. Hence lamivudine is still widely used in Asia. To address these
challenges, the ongoing awareness campaigns, active screening programs, educational activities are needed but must be
enhanced. Cost-cutting measures and international support are essential to improve the diﬃcult situation in this part of
the world.
 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Chronic infection with hepatitis B virus (HBV) is a
global public health problem because of its worldwide
distribution and potential adverse sequelae. An esti-
mated 350 million people around the world are chroni-0168-8278/$36.00  2009 European Association for the Study of the Liver.
doi:10.1016/j.jhep.2009.04.003
Associate Editor: M. Colombo
q The author declared that he has no ﬁnancial and personal
relationships that could inappropriately inﬂuence (bias) his work,
though he has been involved in clinical trials or served as a global
advisory board member of Roche, Bristol-Myers Squibb, Glaxo-
SmithKline, Novartis, Gilead Sciences.
* Tel.: +886 3 3281200x8120; fax: +886 3 3282824.
E-mail address: liveryﬂ@so-net.net.tw
Abbreviations: ALT, alanine aminotransferase; HBV, hepatitis B
virus; HBeAg, hepatitis B e antigen; HCC, hepatocellular carcinoma;
GNI, gross national income; NA, nucleos(t)ide analog; IFN,
interferon.cally infected with HBV. About 75% of them reside in
the Asia-Paciﬁc region, where chronic HBV infection
is usually acquired perinatally or in early childhood
[1,2]. Those chronically infected individuals are at
increased risk of developing hepatic decompensation,
cirrhosis and hepatocellular carcinoma (HCC), and
15–25% will eventually die of HBV-related liver disease.
Obviously, timely management of chronic HBV infec-
tion is of paramount importance. During the past dec-
ades, substantial improvement in the understanding of
HBV virology, host immune response and natural
course, combined with the recent availability of highly
sensitive HBV DNA assays and the advent of eﬀective
antiviral drugs with diﬀerent mechanisms of action,
have led to better therapeutic strategies for chronic
HBV infection. Given their high endemicity of HBV
infection, Asian countries have the greatest opportunity
to beneﬁt from such advancements. However, AsianPublished by Elsevier B.V. All rights reserved.
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lenges ahead.2. Geography, economics and epidemiology of chronic
HBV infection in Asia
Asia consists of more than 40 countries stretching
from Japan westwards to Turkey, with a very large pop-
ulation. Unfortunately, the majority of countries in Asia
have low-income economies (Table 1) and are at high
endemicity of HBV infection (Fig. 1). The 2007 gross
national income (GNI) per capita varied greatly from
country to country in Asia, being >30,000 USD in
Japan, Australia and Singapore, 15,000–30,000 USD
in New Zealand, South Korea and Taiwan, but <905
USD (low-income) or 906–3595 USD (lower–middle-
income) in many countries [3]. Conceivably, the infra-
structure of the healthcare system is not satisfactory in
many lower-income countries [4,5]. The prevalence of
chronic HBV infection also varies among Asian coun-
tries. High-prevalence (P8%) countries include China,
Korea, Philippines, Taiwan, Thailand, Vietnam, and
South Paciﬁc island nations. Intermediate-prevalence
(2–7%) regions include central Asia, Indian continent,
Indonesia, Malaysia and Singapore. Australia and
New Zealand are low-prevalence (<2%) countries but
immigrants from high-prevalence Asian countries in
recent years have increased the burden there. [6]. HBV
genotype distribution also varies. Of the eight genotypes
(A–H) that have been identiﬁed, genotypes B and C areTable 1
Estimated annual cost of drugs and treatment in some Asian countries with di
Country CHB/compensated cirrhosisa De
NAs Peg IFN
Australia 1618–6775 14,627 71
Bangladesh 183–365 14,400 N
China 704–1935 7968 17
India 76–1707 N N
Indonesia 1935–2398 11,040 N
Japan 2097–4220 N N
Malaysia 1044–2084 10,992 N
Philippines 2058–2555 13,713 N
Singapore 1570–2738 13,440 87
South Korea 1314–3285 9600 14
Taiwan 1095–2665 5760 11
Thailand 913–2774 16,464 N
USAc 2482–8694c 18,480c 11
Europed N N 89
*Data of cost in US dollars.
CH-B, chronic hepatitis B; GNI/C, gross national income per capita [3]; HC
analogs; peg IFN, pegylated interferon a2a.
a Abstracted from Ref. [66].
b Data from Refs. [59,61,62,64,65].
c Data from Refs. [60,67].
d Data expressed as median value of France, Italy, Spain and UK. Ref. [6
e Derived from Ref. [3].the major genotypes in most East and Southeast Asian
countries. Genotype B is most prevalent in Taiwan,
genotype C is most prevalent in Korea, Japan and
China, and genotype D is most prevalent in India, cen-
tral Asia, and Mongolia [7–11].
Although universal HBV vaccination in newborns
has been implemented in Asian countries since 1984
[12], there are still large numbers of chronically infected
individuals with HBV in Asia. Taiwan is perhaps the
best example in that the HBsAg prevalence in children
aged <15 decreased from 9.8% in 1984 to 0.7% in 1999
and 0.5% in 2004, 20 years after implementation of uni-
versal HBV vaccination with a coverage of 97% [13].
However, a survey in 157,720 adults aged P18 in Tai-
wan between 1996 and 2005 showed that the overall
prevalence of HBsAg was 17.3% [14], not much less than
the prevalence in studies conducted before 1984 [12].3. Natural course of chronic HBV infection in Asia
The natural history of chronic HBV infection
acquired perinatally or in early childhood has been well
elucidated during the past decades. Asian patients with
chronic HBV infection typically have a long immune tol-
erant phase whereas this phase is not apparent or very
short in patients in Western countries or those who
acquired HBV infection during adulthood [15]. During
the immune tolerant phase, the patients are hepatitis B
e antigen (HBeAg) seropositive with high viral loads
(>2  106–7 IU/ml or >107–8 copies/ml), normal serumﬀerent GNI/C.
compensated cirrhosisb HCCb 2007 GNI/Ce
11 7052 35,960
N 470
02 4740 2360
N 950
N 1650
N 37,670
N 6540
N 1620
94 7036 32,470
19 3044 19,690
73 3066 17,930
N 3400
,459c 7533c 46,040
35d 9048d 36,020
C, hepatocellular carcinoma; N, data not available; NA, nucleos(t)ide
3].
B, C
D
A,D
B, C
B, C
D D
D C
HBsAg prevalence
B, C
≥ 8% = high
2%-7% = intermediate
<2% = low
Fig. 1. Geographic distribution of chronic hepatitis B virus infection and its dominant genotype(s) in Asia. Adapted from CDC traveler’s health, yellow
book, Atlanta GA 2008 [http:/wwwn.cdc.gov/travel/yellowbookch4-HepB.aspx] with modiﬁcation. When two genotypes are common in a region, the
genotype with larger character is the most dominant one.
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[1,15]. Patients who enter the immune clearance phase
usually have intermittent or continuing hepatitis activity
or episodic acute hepatitis ﬂares, sometimes complicated
with hepatic decompensation. These events may lead to
disease progression but may also result in declining
serum HBV–DNA level and eventually lead to sponta-
neous HBeAg seroconversion to its antibody (anti-
HBe) at a rate of 2–15% per year [16]. Following HBeAg
seroconversion, the patients enter a remission or inactive
phase with low serum HBV–DNA (<2000 IU/ml) and
normal ALT [17,18]. Spontaneous HBsAg seroclearance
may occur several years after HBeAg seroconversion at
an annual rate of 0.5–2%, depending on age, HBV geno-
type and underlying disease state [19–22]. HBsAg seroc-
learance usually confers excellent prognosis but HCC
may still occur at a very low rate and usually in those
individuals in whom cirrhosis or superinfection with
other virus(es) had already developed before HBsAg
seroclearance [23].
Active hepatitis may relapse due to reactivation of
HBV with either HBeAg seroreversion (HBeAg-positive
chronic hepatitis) or with precore or basal core prompter
mutations that abolish or down-regulate the production
of HBeAg (‘‘HBeAg negative chronic hepatitis”) [17,18].
Similar to HBeAg-positive hepatitis, most patients withHBeAg-negative hepatitis are asymptomatic even if they
develop an acute hepatitis ﬂare [16]. Therefore, most of
them are detected either during a screening program or
follow-up. The estimated annual incidence of hepatitis
relapse following HBeAg seroconversion was 1.5–3.3%
[17,18,24], being higher in males, genotypes C or D
infected patients and those HBeAg seroconverted after
age 40 [17,25,26], and signiﬁcantly much lower (0.9%/
year) in patients <30 years of age [24].
Patients in the immune tolerant phase or inactive
phase have minimal or no disease progression as long
as serum ALT remains normal [27,28]. The incidence
of cirrhosis is almost zero (1 of 184) during the ﬁrst 18
years of follow-up in those with sustained remission
after HBeAg seroconversion [17]. In contrast, patients
with hepatitis during the immune clearance phase
(HBeAg-positive hepatitis) or reactivation phase
(HBeAg-negative hepatitis) may lead to cirrhosis devel-
opment at an incidence of 2–4% per year, being higher in
males, patients with longer HBeAg-positive or active
hepatitis phase, and those with severe or more extensive
liver injuries [17,18,29,30]. At the onset of cirrhosis
about 50% of the patients are still seropositive for
HBeAg and/or HBV–DNA thus further disease progres-
sion to hepatic decompensation, HCC or mortality may
follow [22]. HCC develops at an annual incidence of 3–
406 Y.-F. Liaw / Journal of Hepatology 51 (2009) 403–4106% in patients with cirrhosis and far less frequently in
non-cirrhotic patients [22,31]. It was calculated that
Asian patients with chronic HBV infection have a lower
proportion of HBeAg-negative hepatitis, lower inci-
dence of cirrhosis but higher incidence of HCC than
their European counterparts [32]. Large, community-
based studies have conﬁrmed that age, sex, HBeAg sero-
status and ALT levels are factors for the development of
liver cirrhosis and HCC. These studies further indicate
that serum HBV–DNA level is associated with cirrhosis
and HCC development at a dose-dependent manner
starting from serum HBV–DNA level >2000 IU/ml
[33–35].
These ﬁndings suggest that HBV replication, with
subsequent immune-mediated liver injuries, is the pri-
mary driving force for liver disease progression [36].
Obviously, both cirrhotic and non-cirrhotic patients
with HBV replication and active hepatitis require eﬀec-
tive therapeutic intervention. In contrast, no drug ther-
apy is required in patients during the immune tolerant
phase or the inactive residual phase.4. Awareness campaigns and active screening program
Most patients with chronic hepatitis B or compen-
sated cirrhosis have few or no symptoms. Thus persons
with chronic HBV infection largely remain undiagnosed.
Detection of these asymptomatic carriers requires active
screening programs, which have been carried out spo-
radically in Asian countries [4]. However, a survey
showed that the diagnostic rate of HBV was only 25%
in USA, 18% in Europe and even lower (4%) in Asia
except Japan (13%) [Decision Resources 2006]. Since
the early 1980s, both the importance and the high prev-
alence of chronic HBV infection have been emphasized
repeatedly through the mass media and other measuresTable 2
Asian patients in pivotal trials of anti-HBV agents.
Trial [Reference] Patient
HBeAg serostatus
LAM/placebo [40] HBeAg-positive
ADV/placebo [42] HBeAg-positive
[41] HBeAg-negative
ETV/LAM [45] HBeAg-positive
[46] HBeAg-negative
[47] LAM-refractory
TBV/LAM [48] HBeAg-positive
[48] HBeAg-negative
TDF/ADV [49] HBeAg-positive
[49] HBeAg-negative
Peg/Peg + LAM/LAM [44] HBeAg-positive
[43] HBeAg-negative
HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; ADV, adefovir; ETV,
telbivudine; TDF, tenofovir.of public education [12]. Screening at blood donation
or upon entry to school, military service and new
employment has become routine practice in Taiwan.
Even so, a survey in 1025 adults aged >30 in Taiwan
showed that only 52% knew about chronic HBV infec-
tion, 54% did not know about any eﬀective therapeutic
medicine for hepatitis B and only 8% reported that they
were chronically infected with HBV [37]. Given the over-
all prevalence of 17.3% in Taiwan [14], it can be calcu-
lated that only 46% of the individuals with chronic
HBV infection in Taiwan were aware that they were
infected. In the highly developed USA, a survey in
3163 Asian American adults showed that only 35% of
the chronically infected persons were aware that they
were infected [38]. Another survey in 6130 Korean-
Americans showed an overall prevalence of 6.1% and,
more importantly, detailed evaluation in 139 incidentally
identiﬁed HBV carriers showed cirrhosis in 11%, chronic
hepatitis in 42% and only 47% were inactive carriers [39].
These ﬁndings highlight the importance of active screen-
ing programs to identify unrecognized victims of chronic
HBV infection for appropriate monitoring and timely
interventions. So far, the awareness among the general
population and HBsAg carriers is far from satisfactory.5. Antiviral therapy for chronic HBV infection: challenges
in Asia
Currently, conventional interferon a (IFN), pegylat-
ed interferon-a2a (Peg IFN), and four nucleoside or
nucleotide analogs (NA) (lamivudine, adefovir, enteca-
vir and telbivudine) have been approved widely in Asia,
tenofovir in a few Asian countries, Clevudine in Korea
only and thymosin a1 in countries including China,
India, Korea, Malaysia, Singapore, Thailand and Viet-
nam [4]. As shown in Table 2, Asian patients were theProportion of patients from Asia (%)
Number
285/73 100/100
171/167 60/60
123/61 29/33
354/355 58/57
325/313 38/41
141/145 25/25
458/463 83/83
222/224 65/64
176/90 36/36
250/125 25/24
271/271/272 87/87/85
177/179/181 60/62/61
entecavir; LAM, lamivudine; Peg-IFN, pegylated interferon a2a; TBV,
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[40–49]. Many important further studies and the longest
experience in the use of these agents have also been
gained in Asian patients [50–54]. Studies from Asia have
shown that IFN-based therapy may reduce ﬁbrosis pro-
gression, decrease cirrhosis and HCC development [29],
and NA therapy may rescue decompensation, reduce
ﬁbrosis progression, reverse cirrhosis and prevent fur-
ther disease progression, including HCC [53–56]. This
array of therapeutic drugs with their short-term/long-
term eﬃcacy has indeed provided a great opportunity
for Asian patients to beneﬁt from these advancements.
Based on these and earlier studies on the natural history
of chronic HBV infection, experts from the region were
able to issue a consensus statement on the management
of chronic hepatitis B as early as year 2000 [57], which
has been updated periodically to its fourth version in
2008 [58].
However, currently available anti-HBV agents are far
from satisfactory and treatment strategies are still evolv-
ing. Problems in drug therapy per se include low ther-
apy-induced HBeAg seroconversion rate, frequent
unpleasant side eﬀects that require close monitoring dur-
ing IFN-based therapy, HBV suppression not durable
after short-term NA therapy, and drug resistance
increases upon prolonged NA therapy. These inherent
problems have made treatment of chronic HBV infec-
tion a complex task that requires individualized assess-
ment and decision, therefore representing a great
challenge to general physicians. A more important and
most critical challenge is the high cost of medical care
and antiviral drugs. Cost analyses have shown that pro-
gression of liver disease is associated with increasing
healthcare costs, and suggest that measures to prevent
progression from chronic hepatitis B to cirrhosis and
its complications would be ﬁnancially beneﬁcial [59–
65]. The major cost of chronic hepatitis B and compen-
sated cirrhosis is that of drug therapy while that of
decompensated cirrhosis and HCC is that incurred with
hospitalization [59–66]. Although the cost of drugs in
Asia seems much lower than that in the USA [67], the
costs are actually much higher when compared with
the GNI per capita of each respective country (Table
1). Lack of full or adequate reimbursement for treat-
ment and diagnostic testing is so common in Asia that
adequate drug therapy is restricted only to those who
can aﬀord it [4]. In central Asia, Turkey is the only coun-
try where all drugs are available and fully reimbursed by
the state [8]. Bangladesh, India, Indonesia, Malaysia and
Philippines had no reimbursement scheme by the end of
2007 [66]. Even in countries with higher GNI per capita
such as Korea, Singapore and Taiwan, there are limita-
tions in the reimbursement of anti-HBV therapy, either
in the selection of agent or the duration of dosing.
Therefore, lamivudine is still widely used in Asia, espe-
cially in countries where generic lamivudine is available[66]. Conceivably, this practice increases the chance of
lamivudine resistance which may negate therapeutic
eﬀect and create new problems [68]. The aforementioned
limitations have made adherence to treatment guidelines
impossible.
Besides lack of reimbursement for treatment and
diagnostic tests, lack of disease awareness among
patients, government and healthcare practitioners are
also obstacles to the proper management of HBV dis-
ease. Lack of disease awareness or understanding of
the disease and fear of stigmatization in society among
patients are associated with poor patient adherence to
therapy or inappropriate health-seeking behavior or
both [5,69]. Lack of awareness among government oﬃ-
cials results in lack of screening programs and inade-
quate reimbursement [4,5,7,66]. Lack of adequate
education and awareness among heath-care providers
is obviously an even more serious problem because ade-
quate explanation, counseling and individualized assess-
ment are essential for successful anti-HBV therapy [58].
In addition, lack of specialists and state-of-art labora-
tory assays are also problems in some countries [5]. Even
if the government and society are well aware of the
problems, costs of screening, monitoring and therapy
may be well beyond their threshold of willingness-to-
pay. These factors not only are responsible for the low
diagnostic rate of HBV in Asia, but also for the low
treatment rate among diagnosed patients (4%, versus
20% in USA, 17–28% in Europe and 8% in Japan) [Deci-
sion Resources 2006]. These contrasting ﬁgures reﬂect
the diﬀerence in the level of development or income of
the countries and also clearly indicate that lack of eco-
nomic resources is the main obstacle to proper manage-
ment of HBV in Asia.6. Facing the challenges in Asia
Tangible measures had to be taken in these circum-
stances. Shortly after the introduction of lamivudine to
Asia, the Asian-Paciﬁc Association for the study of the
Liver (APASL) acknowledged that lack of education
and awareness among healthcare providers was a seri-
ous and widespread problem in many Asian countries.
This led to the publication of guidelines on the manage-
ment of chronic hepatitis B [57,58]. In addition, sup-
ported by independent unrestricted educational grants
from pharmaceutical companies, a group of experts
from the Asian-Paciﬁc region has established a commit-
tee for advancing clinical therapy of HBV and set up
local chapters in many countries since 2005. Provision
of pocket guide books [70], journal supplements [71]
or internet programs, outreach education for primary
care physicians, internists, gastroenterologists and even
hepatologists are ongoing to improve the standard of
care.
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no easy way to overcome the economic disadvantage or
ﬁnancial diﬃculties. This diﬃcult situation is similar to
that of the HBV vaccination program in its early years
in that lack of ﬁnancial resources for infrastructure
and cost of vaccine were major deterrents to countries
[72]. Reduction of vaccine price and international tech-
nical or ﬁnancial support have greatly extended the
HBV vaccination program to many lower-income coun-
tries [72,73]. Similar support will be extremely helpful
for screening, monitoring and antiviral therapy of
chronic HBV infection in lower-income Asian countries.
Before this becomes available, cost-cutting measures
should be implemented. Lamivudine and adefovir are
generics in a few Asian countries already [66]. The cost
of these two drugs is conceivably more aﬀordable in
these countries. Further reduction of prices is needed,
particularly regarding the drugs with higher genetic bar-
riers to resistance. Cost-eﬀective analyses in the speciﬁc
context of each Asian country may help to guide
towards the most cost-eﬀective approach in each respec-
tive country [66]. Application of a road-map concept of
approach, by starting with the cheapest agent and
switching to other agent(s) if serum HBV–DNA is still
detectable at 24 weeks of treatment [74,75], may also
reduce the cost. Perhaps the most important goal is to
educate physicians well enough to ensure that there is
a clear indication for starting therapy and avoid inap-
propriate expansion of indications or unnecessary drug
therapy. It is also important to start therapy in the right
patients at the right time so that the response endpoint
can be achieved earlier hence, shortening the duration
of therapy [58,68].7. Summary and perspectives
Chronic HBV infection is a serious problem in Asia.
The majority of Asian countries are lower-income coun-
tries and at high or intermediate endemicity of HBV
infection, which is usually acquired perinatally or in
early childhood. They are at increased risk of adverse
chronic sequalae, including HCC. Although new gener-
ations of anti-HBV drugs are available, the inherent
problems of the current drugs, lack of awareness among
patients, government, and healthcare practitioners and,
more importantly, high cost and lack of reimbursement
are obstacles to proper management of HBV disease. To
address these problems, awareness campaigns, active
screening programs, educational activities are ongoing
but need to be enhanced. Careful selection of patients,
on-treatment adjustment strategy and every measure
to cut down the cost of treatment are all needed. Cost-
eﬀective analysis in the speciﬁc context of each country
is also necessary to guide the most cost-eﬀective
approach in each of these countries. Financial or techni-cal support from international agencies and reduction of
price by companies producing anti-HBV drugs or HBV
assays would be the most direct and eﬀective measures
to improve the situation.
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